hand foot and mouth disease
Conditions
Interventions
inhaling treatment group:inhaling the recombinant human interferon a1b
control group:support treatment based on the symptoms
Sponsors
The first affiliated hospital of Zhengzhou university
Eligibility
Sex/Gender
All
Age
1 Years to 5 Years
Inclusion criteria
Inclusion criteria: 1. aged 1-5 years; 2. HFMD children diagnosed based on HFMD diagnose criteria; 3. HFMD with any of the following Clinical manifestations: (1) temperature above 38.5 degree C; (2) involved the central nervous system: such as listlessness, dysphoria, headache, vomiting, skittishness, anergia; (3) rate of breathe in peace above 30 time/min, rate of heart >140 time/min; (4) children guardian signed informed consent in paper.
Exclusion criteria
Exclusion criteria: 1. diagnosed as HFMD with severe clinical implication; 2. allergic characterization, espically the children who were allergic to several antibiotics; 3. the children allergic to interferon; 4. Children suffering from congenital heart disease; 5. Children suffering from epilepsy and other central nervous system disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the rate of the severe hand foot and mouth disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| the time of temperatuer recovery;time of skin rash disapparement;count the EV71 before and after; | — |
Countries
China
Contacts
Public ContactSheng Guangyao
Outcome results
None listed